Effect of Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax
The Journal of Infectious Diseases2010Vol. 201(9), pp. 1353–1360
Citations Over TimeTop 22% of 2010 papers
Michael S. Seaman, Marissa B. Wilck, Lindsey R. Baden, Stephen R. Walsh, Lauren E. Grandpre, Colleen Devoy, Ayush Giri, Lizanne C. Noble, Jane A. Kleinjan, Kristen E. Stevenson, Haesook T. Kim, Raphael Dolin
Abstract
MVA immunization results in clinical and virologic protection against Dryvax challenge. Protection is associated with prior induction of neutralizing antibodies to MVA or vaccinia virus. MVA administered intradermally has protective and immunologic responses similar to those of a 10-fold-higher dose given subcutaneously.
Related Papers
- → IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine(2008)125 cited
- → Smallpox and Live-Virus Vaccination in Transplant Recipients(2003)16 cited
- → Prevention of Vaccinia Infection in a Laboratory Worker(2007)3 cited
- → Current infection-control issues for smallpox disease and vaccinia vaccine(2003)3 cited
- Skin reaction following immunization with smallpox vaccine: a personal perspective.(2003)